DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.

Author(s): Langleben D

Affiliation(s): McGill University, Montreal, Quebec, Canada. david.langleben@mcgill.ca

Publication date & source: 2007-03, Clin Chest Med., 28(1):117-25, viii.

Publication type: Research Support, Non-U.S. Gov't; Review

The recognition that endothelin-1 contributes to the pathogenesis of pulmonary arterial hypertension has led to the development of clinically useful endothelin receptor antagonists that improve symptoms and functional capacity and alter the natural history of the disease in a beneficial way. The antagonists have varying degrees of selectivity for the two classes of endothelin receptor, termed ETA and ETB, and the varying degrees may translate into clinical differences. Endothelin receptor antagonists have become an integral part of therapy for pulmonary arterial hypertension, and the indications for their use are expanding.

Page last updated: 2007-08-04

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017